135 related articles for article (PubMed ID: 15072491)
1. Metastatic prostate cancer with normal level of serum prostate-specific antigen.
Nishio R; Furuya Y; Nagakawa O; Fuse H
Int Urol Nephrol; 2003; 35(2):189-92. PubMed ID: 15072491
[TBL] [Abstract][Full Text] [Related]
2. M1 prostate cancer with a serum level of prostate-specific antigen less than 10 ng/mL.
Yamamoto S; Ito T; Akiyama A; Aizawa T; Miki M; Tachibana M
Int J Urol; 2001 Jul; 8(7):374-9. PubMed ID: 11442659
[TBL] [Abstract][Full Text] [Related]
3. Low PSA metastatic androgen- independent prostate cancer.
Sella A; Konichezky M; Flex D; Sulkes A; Baniel J
Eur Urol; 2000 Sep; 38(3):250-4. PubMed ID: 10940696
[TBL] [Abstract][Full Text] [Related]
4. [Recrudescent prostate cancer with a low serum PSA level and a high serum CEA level treated with docetaxel : a case report].
Fujita M; Goto T; Uchida K; Saiki S; Arima R
Hinyokika Kiyo; 2013 Mar; 59(3):183-8. PubMed ID: 23633635
[TBL] [Abstract][Full Text] [Related]
5. Relapsed prostate cancer with neuroendocrine differentiation and high serum levels of carcinoembryonic antigen without elevation of prostrate-specific antigen: a case report.
Kinebuchi Y; Noguchi W; Irie K; Nakayama T; Kato H; Nishizawa O
Int J Urol; 2007 Feb; 14(2):147-9. PubMed ID: 17302572
[TBL] [Abstract][Full Text] [Related]
6. [Recrudescence of prostate cancer with low serum level of PSA and high serum level of CEA and CA19-9: a case report].
Yokoyama S; Fukuhara S; Imazu T; Hara T; Yamaguchi S; Adachi S
Hinyokika Kiyo; 2007 Jul; 53(7):485-7. PubMed ID: 17702183
[TBL] [Abstract][Full Text] [Related]
7. [Prostate cancer with high serum level of CEA and CA19-9: a case report].
Momma T; Kimura S; Saito S; Onoda N
Hinyokika Kiyo; 1998 Mar; 44(3):187-91. PubMed ID: 9589883
[TBL] [Abstract][Full Text] [Related]
8. Prognostic implications of prostate-specific antigen in patients with locally advanced prostate cancer treated with high energy neutron beam therapy: preliminary results.
Saroja KR; Oesterling JE; Hendrickson F; Cohen L; Mansell J
Urology; 1993 Jun; 41(6):540-7. PubMed ID: 7685957
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
10. An assessment of the usefulness of serum prostate-specific antigen level and cancer volume in biopsy specimens to predict the extent of prostate cancer.
Gohji K; Nomi M; Kizaki T; Morisue K; Okamoto M; Takenaka A; Fujii A
Br J Urol; 1997 Apr; 79(4):602-7. PubMed ID: 9126092
[TBL] [Abstract][Full Text] [Related]
11. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density.
Blackwell KL; Bostwick DG; Myers RP; Zincke H; Oesterling JE
J Urol; 1994 Jun; 151(6):1565-70. PubMed ID: 7514689
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy.
Kamiya N; Akakura K; Suzuki H; Isshiki S; Komiya A; Ueda T; Ito H
Eur Urol; 2003 Sep; 44(3):309-14; discussion 314. PubMed ID: 12932928
[TBL] [Abstract][Full Text] [Related]
13. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
14. Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients.
Yashi M; Muraishi O; Kobayashi Y; Tokue A; Nanjo H
Prostate; 2002 May; 51(2):84-97. PubMed ID: 11948963
[TBL] [Abstract][Full Text] [Related]
15. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
16. Carcinoembryonic antigen and carbohydrate antigen 19-9-producing adenocarcinoma of the prostate: report of an autopsy case.
Kodama S; Itoh H; Ide H; Kataoka H; Takehara T; Nagano M; Hamasuna R; Koono M; Osada Y
Urol Int; 1999; 63(3):193-7. PubMed ID: 10738193
[TBL] [Abstract][Full Text] [Related]
17. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients.
Sasaki T; Komiya A; Suzuki H; Shimbo M; Ueda T; Akakura K; Ichikawa T
Eur Urol; 2005 Aug; 48(2):224-9; discussion 229-30. PubMed ID: 16005374
[TBL] [Abstract][Full Text] [Related]
18. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
Alessandro S; Vincenzo G; Maria AG; Stefano S; Alessandro G; Salvatore M; Vincenzo T; Franco DS
Endocr Relat Cancer; 2007 Sep; 14(3):625-32. PubMed ID: 17914093
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
[TBL] [Abstract][Full Text] [Related]
20. Association of serum prostate-specific antigen levels with the results of the prostate needle biopsy.
Janbaziroudsari H; Mirzaei A; Maleki N
Bull Cancer; 2016 Sep; 103(9):730-4. PubMed ID: 27345449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
